Elliott Management Rebuilds Significant Stake In Masayoshi Son’s Softbank, Pushes For $15B Share Buyback: Report
The fund's move comes as the gap between SoftBank's asset value and its market valuation reaches unprecedented levels.
Bye-Bye NYSE, Nasdaq? Wall Street Bigwigs BlackRock, Citadel Lead Charge For New ‘Apolitical,’ ‘CEO-Friendly’ Stock Exchange In Texas
The reported move comes amidst concerns over stringent regulatory requirements laid down by the NYSE and Nasdaq.
Tesla Investor Ross Gerber Thinks Elon Musk’s Decision To Redirect Nvidia AI Chips To X, xAI Is A ‘Weird Excuse’
Gerber added that Musk's motivation for diverting the chips is to focus on robotics and "robotaxi idea" at xAI over autonomous self-driving.
MicroAlgo, CrowdStrike, Core Scientific, Riot Platforms, Tesla: Why These 5 Stocks Are On Investors’ Radars Today
On Tuesday, major U.S. indices finished the day with the Dow Jones Industrial Average rising 0.4% to 38,711.29, the S&P 500 increasing 0.15% to 5,291.34, and the Nasdaq closing up 0.17% at 16,857.05.
These are the top stocks that gained the attention of retail traders and investors throughout the day:
Ross Gerber Cautions ‘Roaring Kitty’ Over Short-Term Gamestop Position As He Has Many Enemies: ‘He’s Got To Sell The Options Soon’
Renowned investor Ross Gerber has cautioned Keith Gill, better known as ‘Roaring Kitty’, about his GME). What Happened:…
‘Buying Call Options Is Not Illegal’: Professional Trader Calls Potential Roaring Kitty Ban ‘Absurd’
Morgan Stanley's E-Trade is reportedly considering a ban on Roaring Kitty's trading account due to potential stock manipulation after he disclosed a $100-million GameStop position. Professional trader criticizes the idea, says buying calls is not illegal.
BridgeBio Pharma Shares One Year Data From Dwarfism Candidate
BridgeBio Pharma revealed results from the PROPEL 2 Phase 2 trial of infigratinib in children with achondroplasia. Key data shows sustained increases in height velocity and improved body proportionality with a good safety profile.
Sanofi Highlights Data From Blood Cancer Drug Sarclisa In New Diagnosed Multiple Myeloma Patients
Sanofi's phase 3 IMROZ study shows Sarclisa with VRd significantly improves progression-free survival in newly diagnosed, transplant-ineligible multiple myeloma patients.
Lululemon Athletica Recovering From Merchandising Missteps, Says Analyst
Oppenheimer analyst Brian Nagel reiterated an Outperform rating for Lululemon Athletica with a $445 price target. Despite a 35% drop in shares post-Q4 results, Nagel remains optimistic, noting a stable EPS forecast and potential recovery from merchandising missteps.
Nvidia Maintains Lead As Key AI beneficiary, Analyst Boosts Estimates After Taiwan Event
Mizuho analyst notes Nvidia's continued growth potential with upcoming products, raising price target for Buy ratings on Nvidia, AMD, and Intel.